Russell Clayton, Chief Medical Officer of Larimar Therapeutics, Inc., filed a Form 4 on November 18, 2026, disclosing a purchase of Larimar common stock on November 16, 2026.

Key Highlights

  • Reporting person: Clayton Russell, Chief Medical Officer of Larimar Therapeutics, Inc.
  • Transaction: Purchase (transaction code P) of 3,322 shares of common stock on November 16, 2026.
  • Price paid: $3.01 per share, according to the filing.
  • Resulting ownership: 74,765 shares of common stock held directly following the transaction.
  • Exchange and ticker: NASDAQ:LRMR, as stated on the filing's issuer line.

Clayton Russell's Open-Market Purchase of Larimar Common Stock

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 18, 2026, Clayton Russell, serving as Chief Medical Officer of Larimar Therapeutics, Inc. (NASDAQ:LRMR), reported an open-market purchase of Larimar common stock. The transaction took place on November 16, 2026, and was filed on behalf of the reporting person by Jennifer Johansson, Attorney-in-fact, whose signature appears on the document.

The filing discloses that Russell acquired 3,322 shares of Larimar Therapeutics common stock at a price of $3.01 per share, with the shares classified as acquired (code "A") under transaction code "P," indicating a purchase. The shares are held directly by the reporting person. No derivative securities transactions were reported in Table II of the filing.

Following the reported transaction, Russell's total direct beneficial ownership of Larimar Therapeutics common stock stands at 74,765 shares, as stated in the filing. No indication is provided in the filing that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox was not marked.

What Was Disclosed

The filing reports a single open-market purchase of 3,322 shares of Larimar Therapeutics common stock by Chief Medical Officer Clayton Russell on November 16, 2026, at $3.01 per share, bringing his direct beneficial ownership to 74,765 shares.